Evidence map›Paper›PMID 40433916›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

PROS1-MERTK Axis Drives Tumor Microenvironment Crosstalk and Progression in Papillary Thyroid Microcarcinoma.

Wenqian Zhang, Ye Zhang, Zhu Liu, Zhiyuan Wang, Huaqin Wang, Xiaoyu Ji, Hongyue Su, Fan Yang, Lirong Yan, Ying Xu and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenqian ZhangDepartment of Head and Neck Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, 110042, China.
Ye ZhangThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Zhu LiuDepartment of Head and Neck Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, 110042, China.
Zhiyuan WangDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Huaqin WangDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China.
Xiaoyu JiDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Hongyue SuDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Fan YangDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Lirong YanThe First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Ying XuSchool of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
Hao ZhangDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Wei SunDepartment of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.ORCID https://orcid.org/0000-0003-1952-128X

Funding

Applied Basic Research Program of Liaoning Province 2022020225-JH2/1013Basic Research Project of Liaoning Provincial Department of Education for Universities LJ242410159046Liaoning Province Science and Technology Joint Plan 2024JH2/102600179National Natural Science Foundation of China 81902726National Natural Science Foundation of China 82073244Natural Science Foundation of Liaoning Province 2020-ZLLH-34Natural Science Foundation of Liaoning Province 2024-MS-052
6 · The paper itself

Abstract

The incidence of papillary thyroid carcinoma (PTC) has been rising annually, with papillary thyroid microcarcinoma (PTMC) accounting for more than half of the cases. While most PTMCs exhibit indolent growth and a favorable prognosis, some undergo clinical progression with poor outcomes. Thus, identifying biomarkers associated with PTC, particularly those related to PTMC progression, is crucial for precise risk stratification and treatment planning. This study utilized single-cell RNA sequencing on 19 surgical tissue specimens from 15 patients, including four para-tumor tissues, four non-progressive PTMCs, five progressive PTMCs, and six progressive PTCs. Key findings are corroborated through in vivo and in vitro experiments. Single-cell RNA sequencing and spatial transcriptomics characterized the cellular ecosystem within PTC, revealing multi-directional evolutionary patterns as PTMC progresses. Analysis of progression-specific alterations in intercellular communication networks highlighted the PROS1-MERTK signaling interaction as pivotal in PTMC progression. In vitro and in vivo models confirm that the PROS1-MERTK axis accelerates PTMC progression via paracrine and autocrine signaling. Furthermore, NFYB and FOXP2 are identified as activators of PROS1 transcription in fibroblasts, promoting PTMC progression through the MERTK/WNT/TGF-β signaling. These findings underscore the PROS1/MERTK axis as a critical component of the cellular microenvironment and a key regulatory mechanism in PTMC progression.

Indexed as

Carcinoma, PapillaryThyroid Cancer, PapillaryThyroid NeoplasmsTumor MicroenvironmentAnimalsDisease ProgressionFemaleHumansMaleMiceMiddle AgedSignal Transductionpapillary thyroid microcarcinomasingle‐cell RNA sequencingtumor microenvironment

Identifiers

PMID40433916
PMCPMC12376618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.